Sotorasib tablets | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Lumakras
Company
Amgen Inc.
Medicine type
Chemical medicine
Therapeutic area
Oncology
Indications recorded in the public source
US: Alone for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer after at least one systemic therapy. With panitumumab for adults with KRAS G12C-mutated metastatic colorectal cancer after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Mutation must be confirmed by an FDA-approved test; the lung-cancer indication uses accelerated approval.
Indication source and scope
US prescribing information revised January 2025. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Overseas official prescribing information linked; a complete current Chinese label has not been verified.
China availability status
Chinese approval, locally approved indications and current availability have not been independently verified in this import.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions